PHILADELPHIA - Olfactory Biosciences Corp (OLFC) today announced that it has signed a distribution agreement with Fisher HealthCare, part of Thermo Fisher Scientific Inc. (TMO), for its new and improved, all natural formulation for NOXO Odor Defense™ and two other NOXO products. All products are immediately available from Fisher Healthcare. NOXO is a special proprietary formulation of Phytonutrients and Phytochemicals taken from plants, flowers, roots and seeds, designed to have far-reaching applications around the world for people who must endure noxious smells.
NOXO is gel, applied topically under the nostrils, specifically formulated to block the physical discomfort, retching, nausea and vomiting associated with offensive and unpleasant odors. NOXO's innovation is to control the effects of offensive and unpleasant odors at the olfactory receptor site whereas other products attempt to control bad odors at the source.
Uniquely formulated NOXO Odor Defense™ is based on advanced olfactory perception altering technology developed by Dr. V Ruth Pinney who is a director of Olfactory Biosciences Corp and who also conducts the research for the company's products at her research facility in The Woodlands Texas.
About Fisher HealthCare
Fisher HealthCare is a leading supplier of diagnostic tests, equipment, chemicals, and other products used by national laboratory networks, independent clinical laboratories, hospitals, and physicians' offices. Information about Fisher HealthCare and its products is available on the company's Web site at www.fisherhealthcare.com.
About Olfactory Biosciences Corp
Olfactory Biosciences Corp.’s NOXO division is focused to develop a variety of products targeting Olfactory Receptors for the desired effect. These alternative medicine wellness products may modify behavior or provide relief to common health problems such as smoking cessation or weight control, as examples.
This company has taken NOBEL Prize science related to discoveries of odorant receptors in the nose and the organization of the olfactory system, and has developed unique wellness products that are affordable and made from all natural ingredients. Olfactory Biosciences Corp. offers the most advanced and innovative wellness products with the potential to change the way we approach wellness issues today. Olfactory Biosciences Corp’s unique advantages will make NOXO products the most sought-after wellness products in the alternative medicine market, creating a growth rate ten times higher than most in the this growing category.
"Safe Harbor" Statement under the PrivateSecurities Litigation Reform Act of 1995: Statements by the Company, statementsregarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the indoor garden market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA
- Investment & Company Information
- Olfactory Receptors